Mesoblast Ltd ADR (MESO) Stock Price, Quote & News

Company Profile

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic ref...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9639 6036

Fax: 61 3 9639 6030

Website: www.mesoblast.com

Address:

55 Collins Street, Level 38, Melbourne, Australia

HedgeFollow Apr. 16 at 4:10 PM

🔍 𝗙𝗥𝗘𝗦𝗛 𝗕𝗨𝗬𝗦 🔎 Among the 𝗟𝗮𝗿𝗴𝗲𝘀𝘁 𝗜𝗻𝘀𝗶𝗱𝗲𝗿 𝗕𝘂𝘆𝘀 in the past week: $NKE - $ 2.2M $LW - $ 6.4M $CHPT - $ 250k $MESO - $ 26.2M Nike being the most notable one especially by who the Insiders were who bought. Source: https://hedgefollow.com/largest-insider-buys.php

0 · Reply

jcooptechit Apr. 16 at 1:33 PM

$CELZ AT A CLINICAL INFLECTION POINT AND DATA + MOMENTUM ALIGNING CELZ isn’t just a story anymore… it’s showing real clinical progress. 🧬 CELZ-201 (Back Pain | ADAPT Trial): ▫️ Phase I/II COMPLETE enrollment ▫️ Positive 180-day data ▫️ 79% patient improvement ▫️ No major safety concerns ▫️ FDA Fast Track Now entering data maturation + next-stage pathway 💥 THE ALPHA: ✅ Early efficacy ✅ Safety validated ✅ Massive market (chronic back pain) This is where small-cap biotech names can rerate FAST. Next catalysts: final data + regulatory progress + potential partnerships. 👀 Clinical validation + technical setup = one to watch closely Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers/ Competitors: $MESO $VRTX $NVAX $MRNA

1 · Reply

S144 Apr. 16 at 8:58 AM

$MESO MESOBLAST ACQUIRES CHIMERIC ANTIGEN RECEPTOR (CAR) PLATFORM TECHNOLOGY FOR PRECISION-ENHANCED CELL PRODUCTS https://investorsmedia.mesoblast.com/static-files/223699d4-0d65-42f7-9530-f5fe7131a89a

0 · Reply

TradersTrader Apr. 15 at 8:58 PM

$TSOI WTG $MESO !!! 👏👏👏👏👏👏👏👏👏👏👏 Another win w FDA for BIO 🤓 https://www.globenewswire.com/news-release/2026/04/10/3272039/0/en/Mesoblast-Receives-IND-Clearance-From-FDA-to-Directly-Proceed-to-Registrational-Trial-for-Approval-of-Ryoncil-in-Duchenne-Muscular-Dystrophy-CORRECTION.html

0 · Reply

Your_friend_Satan Apr. 15 at 1:30 PM

$MESO horny.

0 · Reply

AlertsAndNews Apr. 15 at 2:56 AM

$MESO PR this evening after the AH close Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products "today announced that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell (MSC) products"

0 · Reply

FreePoorR Apr. 13 at 11:47 AM

$MESO 🚀

0 · Reply

FilingTracker Apr. 13 at 11:25 AM

$MESO Large insider purchase (Each ADS represents 10 shares, so $1.44 per share × 10 = $14.40 stock price): https://www.sec.gov/Archives/edgar/data/1345099/000199937126008132/xslF345X06/georgeform4.xml

0 · Reply

Tony_37 Apr. 10 at 11:29 PM

$MESO : looking good 💎

0 · Reply

Oasis2 Apr. 10 at 3:12 AM

$MESO Get ready for a bounce in MESO shares at the start of the trading day. News could potentially be coming soon!

0 · Reply

Mesoblast Acquires CAR Technology From Mayo Clinic To Enhance MSC Therapies

2026-04-15T05:51:53.000Z - 10 days ago

Mesoblast Secures Exclusive CAR-MSC Technology License; Stock Up

2026-04-15T03:26:51.000Z - 10 days ago

Mesoblast (MESO) Secures Global License for Advanced CAR Technology

Apr 14, 2026, 8:10 PM EDT - 10 days ago

Market Cap	2.00B
Revenue (ttm)	17.20M
Net Income (ttm)	-102.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-593.84%
Debt to Equity Ratio	0.22

Volume	87,700
Avg Vol	273,140
Day's Range	N/A - N/A
Shares Out	129.16M
Stochastic %K	45%
Beta	2.19
Analysts	Strong Sell
Price Target	$35.00